1 / 14

HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection

HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection.

alaire
Download Presentation

HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection Alice K. Asher1, RN, MS; Glenn-Milo Santos1, MPH; Jennifer Evans, MS1; E. Kainne Dokubo1, MD; Jeff Martin1, MD; Steve Deeks1, MD; MPH; Leslie Tobler2, Dr.Ph; Mike Busch2, MD, Ph.D.; Peter Hunt1, MD; Kimberly Page1, PhD, MPH 1University of California, San Francisco 2Blood Systems Research Institute, San Francisco, California

  2. Spontaneous clearance of HCV • 20-25% of HCV infected persons spontaneously clear the virus • HIV co-infected: 10-20% • Factors associated with spontaneous HCV clearance: • Sex (Micallef, et al., 2007; Page, et al., 2009) • IL-28B status (Thomas, et al., 2009) • HLA type (Thio, et al., 2002; Kim, et al., 2011) • T cell response (Osburn, et al., 2010) • Micallef, 2007, J. Viral Hepatitis; Matthews, 2008, GasterenterolHepatol

  3. HIV control in the absence of ART • 1-5% of PLWHA are considered ‘HIV controllers’ • Elite controllers: anti-HIV positive; no measurable HIV viremia (<75 copies/mL) • Viremic controllers: anti-HIV positive; measurable low level viremia (75-2000 copies/mL) • HIV controllers are more likely to spontaneously clear HCV • Deeks, 2007, Immunity. • Sadaji, 2010, AIDS; Salgado, 2011, AIDS; Kim, 2011, Gasteroenterology

  4. Host genetic polymorphisms associated with HIV and HCV outcomes

  5. Objective Assess relationship between spontaneous control of HIV and HCV clearance Assess host genetic factors that may explain HCV clearance in HIV controllers

  6. Methods • Participants sampled from SCOPE cohort • >1600 chronically HIV+ patients • Enriched for HIV controllers • HLA typing available • Included: HCV Ab+ (Ortho Clinical Diagnostics®) • Excluded: HBsAg+, Hx of HCV treatment • HCV RNA using discriminatory TMA (Novartis®) • Spontaneous HCV clearance: HCVAb+/RNA- • IL28B genotyping performed

  7. Study population (N=279) † Elite controllers + HIV viremic controllers (<2000 copies/ML without ART for at least 12 months

  8. HCV clearance by HIV controller status

  9. HCV clearance by HIV controller status Differences significant when adjusted for sex, age & race (APR 1.44, p=0.026)

  10. Genetic polymorphisms in HIV controllers and non-controllers

  11. HCV clearance by HLA B*57 and HIV controller status P=0.004

  12. HCV clearance by HLA B*57 and HIV controller status P for interaction =0.01 P=0.004

  13. Conclusions • HIV controllers are more likely to clear HCV infection than non-controllers • While HLA B*57 predicts HCV clearance in HIV non-controllers, it does not fully explain HCV clearance in HIV controllers • >50% B*57- HIV controllers clear HCV • Host factors other than HLA B*57 contribute to the control of HCV in HIV controllers • Identifying these factors may support the development of novel vaccine strategies for HIV and HCV

  14. Special Thanks • SCOPE Study: • Peter Hunt, MD • Melissa Krone • Jeff Martin, MD • Steve Deeks, MD • Kimberly Page, Ph.D., M.P.H. • Milo Santos, M.P.H. • Jennifer Evans, M.S. • Meghan Morris, Ph.D. • E. KainneDokubo, MD • Blood Systems Research Institute: • Leslie Tobler, Dr.Ph • Mike Busch, MD, Ph.D. • Tzong-Hae Lee, MD, Ph.D.

More Related